Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of SD-809 (deutetrabenazine) in moderate to severe tardive dyskinesia
2014-001891-73Phase 3Completed
- Sponsor
- Auspex Pharmaceuticals
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deutetrabenazine in tardive dyskinesia (TD), sponsored by Auspex Pharmaceuticals. Primary endpoint: Incidence of adverse events over long-term deutetrabenazine treatment. Started Aug 2014; status: completed.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2014-001891-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001891-73.